Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.

Abstract: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.

Abstract: The present invention relates to pharmaceutical compositions for oral delivery comprising at least two bioactive proteins associated with glucose metabolism, selected from the group consisting of insulin, proinsulin and C-Peptide in a delivery vehicle adapted for oral administration that provides portal delivery of bioactive proteins. The exemplary pharmaceutical compositions comprise an oil-based matrix comprising solid particulate matter suspended therein, wherein the particulate matter comprises a polysaccharide non-covalently associated with silica particles having a hydrophobic surface, wherein the polysaccharide and silica particles are non-covalently associated with the at least two bioactive proteins. The present invention further provides therapeutic uses of said pharmaceutical compositions.

Abstract: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.

Abstract: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.

Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.

Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.

Abstract: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.

Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.

Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery of insulin, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and insulin suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of insulin.

Abstract: This invention is directed to devices, apparatus, systems and methods for non-invasive sensing of activities occurring within an entity such as an organism. The method comprises sensing at least one characteristic of a current source from under the surface of the entity over a period of time; conveying at least one electrical signal corresponding to the at least one characteristic to an electrolytic cell so as to induce an electrolytic reaction over the period of time; and measuring at least one electrical output of the electrolytic reaction so as to sense at least one activity within the entity over the period of time.

Abstract: Device and method for measuring physiological parameters of a biological being comprising: at least two spaced apart electrodes at least one of which is in contact with-the being for providing a bio-potential measurement including a low frequency AC voltage and/or a DC voltage wherein one of the electrodes is a reference electrode providing a reference for the DC voltage, the low frequency AC voltage and/or DC voltage measurement used to determine the physiological parameters. The device can be built in many forms (e.g. a wrist watch, torso strap, grip, etc); can measure physiological parameters including those related to diabetes (BGL), cardiovascular, organ, tissue, brain and neural function, local and limb metabolic condition, pharmacokinetic, pharmaco-dynamics and psychological conditions, temperature, or combination thereof and their trends. The device can include an automatic alarm system for warning a patient of an out of tolerance condition.